Enveric Biosciences (STU:SLZ) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences 3-Year Dividend Growth Rate?

Enveric Biosciences's Dividends per Share for the three months ended in Dec. 2024 was €0.00.

The historical rank and industry rank for Enveric Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:

STU:SLZ's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.95
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Enveric Biosciences's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Enveric Biosciences's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Enveric Biosciences's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Enveric Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's 3-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

Enveric Biosciences 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Enveric Biosciences (STU:SLZ) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Enveric Biosciences's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-4.582
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences 3-Year Dividend Growth Rate Related Terms>

Enveric Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

ENVB:USA

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.